INI-CET 2022 — Community Medicine

12 Questions — Page 2 of 2

Q11

Which of the following regarding the vaccine vial monitor (VVM) is true? 1. It is used for monitoring heat exposure of the vaccine by healthcare workers in primary healthcare. 2. It shows cumulative exposure of the vaccine to the heat. 3. It can be used to assess the potential efficacy of the vaccine 4. Calculation of the expiry date can be done using VVM. 5. The expiry date of the vaccine can be relaxed if VVM is an acceptable range. 6. If the square and the circle are the same in color, then the vaccine can be safely used.

Q12

Under the Anaemia Mukt Bharath initiative, mild to moderate anaemia in pregnant women <34 weeks of gestation is treated using:

INI-CET 2022 - Community Medicine INI-CET Practice Questions and MCQs

Question 11: Which of the following regarding the vaccine vial monitor (VVM) is true? 1. It is used for monitoring heat exposure of the vaccine by healthcare workers in primary healthcare. 2. It shows cumulative exposure of the vaccine to the heat. 3. It can be used to assess the potential efficacy of the vaccine 4. Calculation of the expiry date can be done using VVM. 5. The expiry date of the vaccine can be relaxed if VVM is an acceptable range. 6. If the square and the circle are the same in color, then the vaccine can be safely used.

A. 1,2,3,4,5
B. 3,4
C. 1,2 (Correct Answer)
D. 5,6

Explanation: ***Correct: Statements 1, 2*** **Statement 1 - TRUE**: The VVM is primarily designed for **healthcare workers** to monitor vaccine heat exposure at all levels, including primary healthcare settings. This is a key WHO tool for cold chain monitoring. **Statement 2 - TRUE**: VVMs provide a **cumulative record** of time and temperature exposure, reflecting the total heat stress a vaccine has experienced throughout its journey from manufacturer to administration. *Statement 3 - FALSE* - While VVMs assess heat exposure that affects vaccine stability, they do **not directly measure vaccine efficacy** or provide quantitative measures of immune response potential. - Heat damage indicated by VVM indirectly suggests reduced potency, but the VVM itself cannot assess efficacy. *Statement 4 - FALSE* - VVMs are **not used to calculate expiry dates**. Manufacturing expiry dates are determined through stability studies under controlled conditions by the manufacturer. *Statement 5 - FALSE* - The **expiry date cannot be relaxed or extended** based on VVM status. The manufacturer's stated expiry date must always be respected regardless of how favorable the VVM reading is. *Statement 6 - FALSE* - This is the **opposite** of how VVM works. If the **inner square is the same color or darker than the outer circle**, the vaccine has been exposed to excessive heat and **should NOT be used**. - The vaccine is safe when the inner square is lighter than the outer circle.

Question 12: Under the Anaemia Mukt Bharath initiative, mild to moderate anaemia in pregnant women <34 weeks of gestation is treated using:

A. IM ferric carboxy maltose (FCM)
B. IV iron sucrose for non-compliance with oral tablets
C. 2 iron and folic acid tablets OD+IV iron sucrose
D. 1-2 IFA tablets daily (depending on severity) (Correct Answer)

Explanation: ***1-2 IFA tablets daily (depending on severity)*** - The **Anaemia Mukt Bharat (AMB)** guidelines recommend **oral iron and folic acid (IFA)** supplementation as the primary treatment for mild to moderate anaemia in pregnant women <34 weeks gestation. - **Mild anaemia (Hb 10-10.9 g/dL):** 1 IFA tablet daily (100 mg elemental iron + 500 mcg folic acid) - **Moderate anaemia (Hb 7-9.9 g/dL):** 2 IFA tablets twice daily (total 200 mg elemental iron per day) - Oral IFA is safe, cost-effective, and addresses the underlying nutritional deficiency. *IM ferric carboxy maltose (FCM)* - **Intramuscular (IM) iron** formulations like FCM are generally reserved for cases of severe anaemia, malabsorption, or intolerance to oral iron. - For mild to moderate anaemia, IM iron is not the **first-line treatment** under AMB guidelines due to potential injection site reactions and the effectiveness of oral alternatives. *IV iron sucrose for non-compliance with oral tablets* - **Intravenous (IV) iron sucrose** is indicated for specific situations such as severe anaemia (Hb <7 g/dL), significant malabsorption, documented intolerance, or persistent non-compliance with oral iron. - However, for mild to moderate anaemia, efforts are made to ensure compliance with oral treatment before resorting to **parenteral iron**, particularly given its higher cost and need for administration in a healthcare setting. *2 iron and folic acid tablets OD+IV iron sucrose* - Combining **oral iron tablets with IV iron sucrose** is not recommended for mild to moderate anaemia under AMB guidelines. - This approach would be considered **overtreatment** for mild to moderate anaemia in the absence of severe anaemia or documented failure of oral therapy despite good compliance.